Leukemia

Leukemia is a monthly, peer-reviewed medical journal published by Springer Nature within its Nature Portfolio, founded in 1987 and covering all aspects of the research and treatment of leukemia and allied diseases, with a 2025 Journal Impact Factor of 8.8《Leukemia》是（Springer Nature）在其（Nature Portfolio）出版的月刊医学期刊，实行同行评审，1987 年创办，覆盖白血病及相关疾病研究与治疗的各个方面，2025 年影响因子为 8.8。

Scope

• Leukemia publishes high-quality, peer-reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases该刊发表高质量的同行评审研究，覆盖白血病及相关疾病研究与治疗的各个方面。
• Studies of normal haemopoiesis are included because of their comparative relevance由于具有比较价值，正常造血的研究也被纳入其中。
• Topics of interest include oncogenes and growth factors, leukaemia stem cells, leukaemia genomics, the cell cycle and signal transduction关注的议题包括致癌基因与生长因子、白血病干细胞、白血病基因组学、细胞周期与信号转导。
• Molecular targets for therapy and the development of targeted and cellular therapies also fall within its scope治疗性分子靶点以及靶向与细胞疗法的开发也在其范围之内。
• Content types include original research articles, reviews, letters, correspondence and comments文章类型包括原创研究论文、综述、快报、通信与评论。
• The journal also publishes the classification and nomenclature material of the World Health Organization for haematological tumours该刊还刊载（World Health Organization）关于血液肿瘤的分类与命名资料。
• Coverage extends to myeloid and lymphoid neoplasms and to both clinical and translational research其覆盖范围延伸至髓系与淋系肿瘤，兼顾临床与转化研究。

History

• Leukemia was founded in 1987 by Nicole Muller-Berat Killmann and Sven-Aage Killmann, pioneers of leukaemia research, and its first issue appeared in January 1987 as volume 1, number 1该刊由白血病研究先驱（Nicole Muller-Berat Killmann）与（Sven-Aage Killmann）于 1987 年创办，第 1 期于 1987 年 1 月以第 1 卷第 1 期面世。^[1]
• Since January 1991 it has been published on behalf of the Sven-Aage Killmann Leukemia Foundation自 1991 年 1 月起，该刊以（Sven-Aage Killmann Leukemia Foundation）名义出版。
• It has also been associated with the Leukemia Society of America and the Leukaemia Research Fund该刊还与（Leukemia Society of America）及（Leukaemia Research Fund）相关联。
• It has been published in London by the specialist journals of Nature Publishing Group since 2000, and it is now part of Springer Nature自 2000 年起，该刊在伦敦由（Nature Publishing Group）的专业期刊部门出版，现属（Springer Nature）。
• The journal appears monthly with 12 issues a year, and it also publishes supplements该刊按月出版，每年 12 期，并另出增刊。
• Its Journal Impact Factor moved from 11.528 in 2021 and 12.883 in 2022 to 13.4 in 2024 and 8.8 in 2025, and the 2025 five-year Journal Impact Factor is 10.7其影响因子由 2021 年的 11.528 与 2022 年的 12.883，变为 2024 年的 13.4 与 2025 年的 8.8，2025 年的五年影响因子为 10.7。^[2]

Editors

• The editors-in-chief are Robert Peter Gale of Imperial College London and Andreas Hochhaus of Jena University Hospital主编为（Imperial College London）的（Robert Peter Gale）与（Jena University Hospital）的（Andreas Hochhaus）。
• Around 25 associate editors oversee the journal, among them Christian Buske, Nicholas C. P. Cross, Christine J. Harrison, Jean-Jacques Kiladjian, Charles G. Mullighan and Vincent Rajkumar该刊约有 25 位副编辑，其中包括（Christian Buske）、（Nicholas C. P. Cross）、（Christine J. Harrison）、（Jean-Jacques Kiladjian）、（Charles G. Mullighan）与（Vincent Rajkumar）。
• Its editorial board of about 50 members is drawn from Germany, the United States, the United Kingdom, Italy, France, Spain, Japan, Poland and China其约 50 人的编委会成员来自德国、美国、英国、意大利、法国、西班牙、日本、波兰与中国。
• The editors strongly support the HUGO Gene Nomenclature Committee recommendation to designate fusion genes with double colons, and they ask authors to follow that nomenclature编委会大力支持（HUGO Gene Nomenclature Committee）以双冒号标示融合基因的建议，并要求作者遵循该命名法。
• Submissions receive a median first editorial decision within three days and a median acceptance time of 119 days投稿自送达到首次编辑决定的中间值为 3 天，接受到录用的中间值为 119 天。
• The journal publishes occasional guest-edited collections, such as its focus issues on CAR-T cell therapy and on myeloproliferative neoplasms该刊不定期推出客座编辑专题，如其关于 CAR-T 细胞治疗与骨髓增殖性肿瘤的重点专题。